These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cordier Kellerman L; Valeyrie L; Fernandez N; Opolon P; Sabourin JC; Maubec E; Le Roy P; Kane A; Legrand A; Abina MA; Descamps V; Haddada H Cancer Gene Ther; 2003 Jun; 10(6):481-90. PubMed ID: 12768194 [TBL] [Abstract][Full Text] [Related]
4. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758 [TBL] [Abstract][Full Text] [Related]
5. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267 [TBL] [Abstract][Full Text] [Related]
6. Vaccination with beta(2)-microglobulin-deficient dendritic cells protects against growth of beta(2)-microglobulin-deficient tumours. Dammeyer P; Mwakigonja AR; Rethi B; Chiodi F; Wolpert EZ Scand J Immunol; 2009 Jul; 70(1):44-52. PubMed ID: 19522767 [TBL] [Abstract][Full Text] [Related]
7. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188 [TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032 [TBL] [Abstract][Full Text] [Related]
9. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514 [TBL] [Abstract][Full Text] [Related]
10. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672 [TBL] [Abstract][Full Text] [Related]
11. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
12. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Liepins A; Nowicky JW Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312 [TBL] [Abstract][Full Text] [Related]
13. Antitumor vaccination: where we stand. Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658 [TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Maletzki C; Linnebacher M; Kreikemeyer B; Emmrich J Gut; 2008 Apr; 57(4):483-91. PubMed ID: 18025068 [TBL] [Abstract][Full Text] [Related]
15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
17. Unconventional NK1.1(-) intermediate TCR cells as major T lymphocytes expanding in chronic graft-versus-host disease. Miyakawa R; Miyaji C; Watanabe H; Yokoyama H; Tsukada C; Asakura H; Abo T Eur J Immunol; 2002 Sep; 32(9):2521-31. PubMed ID: 12207336 [TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
19. Concurrent allorecognition has a limited impact on posttransplant vaccination. Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285 [TBL] [Abstract][Full Text] [Related]
20. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. LaTemple DC; Abrams JT; Zhang SY; Galili U Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]